By Sahithi Kuravi (Mestag Therapeutics Limited)2023-09-19T16:30:46
Recent regulatory changes in the US and Europe are driving the adoption of advanced 3D cell-based technologies, such as organoids and organ-on-chips, in drug development, replacing traditional animal testing and offering safer, cost-effective alternatives.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-03-20T13:41:33
Sponsored by Bio-Techne
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2023-07-04T10:05:58
Sponsored by Revvity
2024-01-26T13:22:42
Sponsored by bit.bio
2023-03-28T11:38:32
Sponsored by Bio-Techne
2024-01-10T08:56:17
Sponsored by Leica Microsystems
Site powered by Webvision Cloud